SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals settles patent litigation with Novartis

15 Jun 2012 Evaluate

Alembic Pharmaceuticals and Breckenridge Pharmaceutical Inc, USA have settled their Paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon by Novartis, and that the US Food and Drug Administration (USFDA) approved their abbreviated new drug application (ANDA). With this, the companies will launch product immediately.

Alembic Pharmaceuticals is the sponsor and manufacturer of the ANDA, which will be marketed exclusively by Breckenridge. Under the terms of the settlement agreement, Novartis has granted Breckenridge and Alembic a license to market a generic version of Exelon before the expiration of US Patent No. 5,602,176, on February 11, 2014.

Rivastigmine Tartrate Capsules is a prescription medicine that is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type, and for the treatment of mild to moderate dementia associated with Parkinson’s disease.

Alembic Pharmaceuticals (APL) was incorporated in June 2010 after the demerger of core pharmaceutical business of erstwhile Alembic, one of the oldest pharmaceutical companies in India. APL is an integrated company having presence across the pharmaceutical value chain.

Alembic Pharma Share Price

736.95 1.25 (0.17%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×